COVID-19

 

HOVON:

We would like to inform you that the HOVON Data Center (HDC) and the HOVON Safety Desk will remain fully operational to ensure the safety of the patients included in HOVON trials.

The distribution and delivery of the study medicinal products are being closely monitored and we will inform you accordingly if any actions need to be taken.

The central laboratories are also still fully functioning.

At the moment it is possible to include patients in all active HOVON trials.

 

Participating sites:

Please make sure to inform the HOVON Data Center per e-mail (hdc@erasmusmc.nl) if your hospital has decided to temporarily halt patient inclusion in clinical trials following the COVID-19 outbreak.

In case patient visits or study procedures cannot be performed per protocol due to the COVID-19, please document this in the patient files.

 

Contact:

Given the situation surrounding the Corona virus, the HOVON central Office (HCB) and the HOVON Data Center (HDC) are temporarily unavailable by phone.

Please send all (urgent) question via email, these will be picked up and processed by the team as soon as possible. We hope for your understanding of this situation.

For study specific questions, you can contact the concerning HOVON Trial Manager or our general e-mail address (hdc@erasmusmc.nl - Please include HOVON study number as reference). Thank you for your cooperation.

 

HOVON Central Office (HCB): hovonbureau@vumc.nl

HOVON Data Center (HDC): hdc@erasmusmc.nl

 

With kind regards, Marleen Breems (HOVON General Director) and Bianca Backx (manager HDC)


SLUITEN
sluit venster

Log in

Username Password Forgotten your user name and/or password? Want to request a user name and/or password?

Search in the HOVON website

Studies MM (Multiple Myeloom)


Study name Status Echelon level Stage Age Updated Included patients Active sites
HOVON-associated EMN17 Perseus Trial Closed Level A - 18-70 09-12-2019 n/a n/a
HOVON 149 AL Amyloidosis Closed n/a - 18 - 70 03-05-2018 n/a n/a
HOVON 147 SMM Open Level C-HIC 2nd line >=18 years 08-10-2019 14 6
HOVON 143 MM Closed Level D 1st line > 18 26-09-2019 130 49
HOVON 131 MM / IFM 2015-01 Closed n/a 1st line 18-65 24-09-2019 n/a n/a
HOVON 129 PCL Open Level A 2nd line >18 yrs 18-02-2020 n/a 23
HOVON 126 MM Closed Limited site selection 1st line 03-05-2018 143 40
HOVON 123 MM Closed Level D 1st line >= 75 15-05-2019 240 46
HOVON 114 MM Open Limited site selection 2nd line >= 18 24-02-2020 n/a 33
HOVON 108 MM Closed Level A 2nd line 18-65 19-10-2018 30 7
HOVON 104 AL AMYLOIDOSIS Closed n/a 1st line 18-70 07-12-2018 57 18
HOVON-associated MM and haplo Closed n/a 3rd line < 66 yrs 12-03-2020 n/a n/a
HOVON 95 MM Closed Level D 1st line 18-65 24-02-2020 n/a 189
HOVON 87 MM Closed Level D 1st line prev. untreated > 65 or <=65 when inelig. for HDT & PCST 05-08-2019 643 90
HOVON 86 MM Closed Level C-HIC & C-SCT 2nd line >=18 03-05-2018 81 25
HOVON 76 MM Closed n/a 1st line 18 - 66 19-10-2018 35 8
HOVON 65 MM / GMMG HD4 Closed n/a 1st line 18 - 65 03-12-2019 828 75
HOVON 57 MM Closed n/a 1st line >= 18 03-05-2018 24 10
HOVON 54 MM Closed n/a 1st line 18 - 65 20-06-2018 87 6
HOVON 50 MM Closed n/a 1st line 18 - 65 03-05-2018 555 n/a
HOVON 49 MM Closed n/a 1st line > 65 03-05-2018 344 n/a
HOVON 41 AL Amyloidosis Closed n/a 1st line < 66 03-05-2018 70 13
HOVON 36 MM Closed n/a 1st line > 64 03-05-2018 69 49
HOVON 24 MM / OG 96-020 Closed n/a 1st line < 66 03-05-2018 n/a n/a